Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kungsleden in major initiative in Västerås

Collaborative project approved for FinnslättenThe collaborative project based on ideas from “Vision Finnslätten” has now been approved by the Building Committee in Västerås. Kungsleden, in cooperation with ABB, commenced the preparatory work on Vision Finnslätten in 2018 and activities are fully under way to develop a train stop, an international school and a campus area, among other features.   In 2018, Kungsleden initiated a dialogue with its largest tenant at Finnslätten, ABB, on the development of the area. The ideas were discussed further with the City of Västerås, which

Pexip – increase of share capital following exercise of employee share options, and limited share sale by primary insiders

Oslo, 18 March 2021: Following vesting and exercise of previously issued employee options, the Board of Directors of Pexip Holding ASA ("Pexip" or the "Company", Oslo Børs ticker "PEXIP") has resolved, based on authorisation granted by the Company's general meeting held on 20 March 2020, to issue 2,253,896 new shares for an aggregate subscription price of NOK 72,320,810. The shares have been subscribed for by various employee option holders. The Company has also in cooperation with ABG Sundal Collier ASA, Carnegie AS and Pareto Securities AS (“the IPO syndicate”) facilitated a

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the "Company") on 17 March 2021 (the "AGM") where election of members to the board of directors was according to the nomination committee’s proposal. At the same AGM of the Company the board of directors was authorized to extend the Company’s restricted stock unit ("RSU") program and to issue RSUs to the board members. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.10 per share (corresponding to the nominal value of the shares) subject to

Embracer Group successfully completed a directed issue of 36,000,000 new B shares raising proceeds of roughly SEK 7.6 billion (approximately USD 890 million)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE INFORMATION: Embracer Group AB (the "Company" or “Embracer Group”) has, as announced in its press release on March 17, 2021, carried out an issue of 36,000,000 new Class B shares directed to institutional investors, resolved upon by the Board of

Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

Oslo, Norway, 17 March 2021 Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun as Chief Executive Officer (CEO). He will take up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland. Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”). During his career at Roche, Mr Braun led the Lifecycle Management

Reviewing Notice to Annual General Meeting in Bioservo Technologies AB (publ)

The shareholders of Bioservo Technologies AB (publ), reg. no. 556650-7264 (”Company”), are hereby summoned to the annual general meeting on Monday 19 April 2021 at 4.00 p.m.,  Torshamnsgatan 35, Kista.With regards to the risks related to the spread of the Coronavirus (COVID-19), Bioservo has decided to take the following precautionary steps at the Annual General Meeting:•    No food or drink will be served.•    Participation by both Board of Directors and Management will be restricted.•    The duration of the General Meeting will be reduced, but without infringing on the rights of

Notice of extraordinary general meeting in Ascelia Pharma

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.   The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797 (“Ascelia Pharma”), are hereby invited to the extraordinary general meeting to be held on Tuesday 13 April 2021.In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has decided that the meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means

The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH

· Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in haemoglobin levels and showed improvements in key clinical outcomes · Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the EMA STOCKHOLM, Sweden and WALTHAM, Mass, USA  - Swedish Orphan Biovitrum AB (publ) (Sobi™)  (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (

Ascelia Pharma has carried out a directed new share issue raising SEK 200 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has successfully carried out a directed new share issue of 5,000,000 ordinary

BioGaia Invest (BGI) – a new subsidiary focusing on innovative investments to support the growth of BioGaia

As part of BioGaia AB’s ambition to grow and develop as an innovative life science company, a separate entity, BioGaia Invest (BGI), has been established. The focus of BGI will be to identify and invest in smaller companies focusing on ground-breaking technologies, services and products that will support the growth of BioGaia.To fuel continued strong growth and to stay in the forefront of research and innovation, BioGaia AB has created BioGaia Invest (BGI). A total of SEK150 million has been allocated to BGI to enable investments between SEK 5 to 15 million in exciting new companies

Addtech acquires ESi Controls Ltd

Addtech Power Solutions, a business area in the Addtech Group, has today signed an agreement to acquire 100% of the shares outstanding in ESi Controls Ltd. ESi (Energy Saving Innovative) Controls is a UK based company designing and delivering energy efficient electronic controls for heating and smart building applications. ESi Controls Ltd has a turnover of approximately GBP 8 million and have 15 employees. ESi will very effectively complement and strengthen Addtech's sustainability initiatives with its focus on providing bespoke energy efficient controls for major National and

Citycon Oyj: Flagging notification in accordance with Chapter 9 Section 10 of the Finnish Securities Markets Act

Citycon Oyj   Stock Exchange Release   17 March 2021 at 20:45 hrsCitycon Oyj has received on 17 March 2021 the following notification pursuant to Chapter 9, Section 5 of the Finnish Securities Market Act from CPP Investment Board European Holdings S.à r.l.:n (”CPPIBE”) according to which their total holding of shares of Citycon Oyj has decreased below ten (10) percent on 17 March 2021.As a result of the disposal, the Governance Agreement entered into between CPPIBE and Gazit-Globe Ltd. on 12 May 2014, as disclosed by Citycon Oyj through stock exchange releases on 13 May 2014 and 17 March

How to succeed with subscriptions in consumer goods: Lessons from the Best-in-class companies

Simon-Kucher & Partners and Babson College analyzed factors of success with subscriptions in the consumer goods sector.[Boston, MA] March 17, 2021 – In Spring 2020, the COVID-19 pandemic forced companies into a world of uncertainty. Consumers shifted to online shopping in record numbers, and the internet became the platform of choice to buy anything and everything. The boom in online shopping amplified customer interest in subscriptions across various consumer markets such as fashion, beauty, pet care, and childcare, with an already well-established reputation in digital and news media

Prime Minister backs growth of UK bioscience industries

PRIME Minister Boris Johnson today (Wednesday) identified bioscience as one of the UK’s growth areas for the future. Speaking in the House of Commons at Prime Minister’s Questions, Mr Johnson outlined a bright future for bioscience industries in the UK. He was responding to a question from Barrow and Furness MP Simon Fell relating to the recent announcement by GSK that it looks set to close its factory in Ulverston, Cumbria. GSK’s announcement comes at a time when a different company, Lakes BioScience has been granted planning permission to start work on a £350m biomanufacturing

Embracer Group announces intention to carry out a directed share issue of B shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE INFORMATION: Embracer Group AB (the "Company" or “Embracer Group”) hereby announces its intention to carry out a directed share issue of approximately 32 million Class B shares, which is intended to be resolved upon by the Board of Directors based on

Ascelia Pharma intends to carry out a directed new share issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has mandated Danske Bank and Pareto Securities (the "Bookrunners”) to evaluate

Romanian sea rescue organsiation selects the RescueRunner system

Yet another sea rescue organisation in Europe has now selected the RescueRunner system for their important but also very challenging work. This time it's a Romanian organisation.The RescueRunner system is since many years back used by numerous sea rescue organisations across the world. We are very glad to announce that our distributor in Romania Suszi S.R.L will now deliver another RescueRunner system to a national sea rescue organisation that has decided to integrate it in their operations. We proudly delivered some of our other boat models to the Romanian market last year, for the life

Decisions of the Annual General Meeting of Finnair Plc

Finnair Plc               Stock Exchange Release              17 March 2021 at 6.20 p.m. EET The Annual General Meeting (AGM) of Finnair Plc was held today at the headquarters of the company in Vantaa, Finland under special arrangements due to the Covid-19 pandemic. 204 shareholders representing 930 553 519 shares and votes were represented at the meeting. The meeting approved the company’s annual accounts and consolidated annual accounts for the financial year 2020, discharged the members of the Board of Directors and CEO of the company from liability and resolved to approve the

instagrid welcomes new member to advisory board for internationalisation

●      Pierre-Pascal Urbon, ex-CEO of SMA Solar Technology AG, has been appointed the new chairman of the battery startup’s advisory board. ●      Urbon will provide support for the expansion of operations abroad. ●      The goal is for instagrid to become an international driving force in off-grid energy storage technology.Ludwigsburg, 17/03/2021 – Battery manufacturer instagrid has welcomed a proven expert of the energy transition and an experienced manager to the company. Pierre-Pascal Urbon (50), former CEO of SMA Solar Technology AG, has taken over as chairman of the advisory

Ponsse Plc Annual Report for 2020 is published

Ponsse Plc’s Annual Report for 2020 including financial statements, Board of Director´s report and responsibility report has been published in Finnish and English on the Ponsse Plc website at https://www.ponsse.com/company/investors  and is attached to this release as a PDF file. The printed Annual Report will be sent by mail to those who have ordered it. Printed Annual Report can be ordered on the Ponsse website or by phone, tel. +358 20 768 800.   Vieremä, 17 March 2021 PONSSE PLC FURTHER INFORMATION:CFO Petri Härkönen, tel.

Updated timetable regarding Calmark's LDH test for Covid-19 assessment

Calmark Sweden AB announces today that the timetable for the development project related to the product COVID19-LDH has been updated. The CE marking of this POC test will take place one to two weeks later than previously disclosed."Verification and validation of COVID19-LDH is currently underway, as announced on 18 February. This phase is expected to be completed shortly after Easter”, comments Anna Söderlund, CEO. "After this, we expect to be able to quickly complete the transfer to production and CE mark the product."

CELLINK publishes Annual Report 2019/2020

CELLINK has published Annual Report 2019/2020 for the financial year which covers September 1, 2019 to December 31, 2020. The Annual Report is available on CELLINK’s website: www.cellink.com/investors. The printed version of Annual Report 2019/2020 will be available during calendar week 13.    For more information, please contact:Isabelle Ljunggren, Head of Communications CELLINKPhone: +46 708-30 08 90Email: il@cellink.com This is information that CELLINK is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 16:50 CET

Blika increases revenue by 30 percent in 2020: “We see huge potential for further growth”

The year 2020 was a successful year for Blika, growing their revenue stream by over 30 percent, signing new clients from all over Europe, and attracting talented coworkers to the company. The objective ahead is to maintain the growth, both in Europe and abroad, with focus on a few key markets such as Germany. “2020 has been a year of significant growth financially, as well as in our customer base and product developments. We will continue to strengthen and improve our market-leading platform and help legal and tax departments all over the world to automate their work and take their first

There are no items matching the current filter
There are no more items matching the current filter
Back to top